/
ELTX
$4.00+$0.00 (+0.00%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$76.3M
19M shares
52-week range
$2.66 – $16.00
10% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
183.37%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-14.14
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.0M | $1.5M | $2.9M | $28.3M | $0 | $0 | $0 | $0 |
| Cost of revenue | $380.0K | $1.1M | $1.8M | $1.2M | $1.1M | $1.2M | $1.2M | $1.1M |
| Gross profit | $3.6M | $351.0K | $1.1M | $27.1M | −$1.1M | −$1.2M | −$1.2M | −$1.1M |
| Gross margin | 90.6% | 23.6% | 36.9% | 95.6% | — | — | — | — |
| R&D | $9.2M | $29.8M | $38.9M | $48.6M | $17.0M | $22.7M | $33.7M | $24.9M |
| Operating income | −$14.3M | −$38.6M | −$55.3M | −$39.3M | −$23.7M | −$35.7M | −$45.0M | −$37.7M |
| EBITDA | −$14.3M | −$40.2M | −$70.6M | −$51.9M | −$23.6M | −$33.0M | −$50.3M | −$37.3M |
| Net income | −$20.0M | −$40.7M | −$80.1M | −$26.4M | −$28.2M | −$35.2M | −$51.9M | −$39.6M |
| Net margin | -497.0% | -2734.2% | -2781.5% | -93.2% | — | — | — | — |
| EPS (diluted) | -6.79 | -1.50 | -1.93 | -19.32 | -9.10 | -6.96 | -4.25 | -2.58 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $20M | $-2.13 | $-2.35–$-1.79 | 3 |
| 2027 | $0 | $-2.64 | $-2.70–$-2.57 | 2 |
| 2028 | $0 | $-2.70 | $-3.30–$-2.10 | 2 |
| 2029 | $0 | $-4.00 | $-4.00–$-4.00 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.22
Price
$4.00
Implied downside
-94%
Peer comparison
Elicio Therapeutics, Inc. Common Stock
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
www.elicio.com- Employees
- 33
- IPO / List date
- Jun 2, 2023
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds ELTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 121,631 | $1.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ELTX yet.
